ОбзорГрафикПрофильОсновная статистикаФинансовые показателиТехническийНовости
Деривативы
TraderScreen

IDORSIA N/  CH0363463438  /

SIX Swiss Exchange
11.11.2024  13:34:29 Изменение -0.1215 Объем сделки Бид13:36:04 Предложение13:36:04 Рыночная капитализация Дивидендная доходность Коэффициент Цена/Доход
0.9535CHF -11.30% 1.04 млн
Оборот: 1.02 млн		 0.9405Величина цены спроса: 1,903 0.9535Величина цены предложения: 2,249 179.72 млнCHF - -
GlobeNewswire 13.08 Santhera Closes Financings and Secures Funds to Reach Break-Even Expected in 2026
GlobeNewswire 09.08 Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2...
GlobeNewswire 24.06 Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
GlobeNewswire 18.06 Santhera Secures up to CHF 69 million in Royalty and Debt Financing to Fund Operations to Cash Flow ...
GlobeNewswire 22.05 Invivyd Elects Two New Independent Members to its Board of Directors
GlobeNewswire 09.05 Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024
GlobeNewswire 17.04 Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determ...
GlobeNewswire 01.04 Nxera Pharma is the New Name for Sosei Group
GlobeNewswire 27.03 Sosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of C...
GlobeNewswire 28.02 Idorsia and Viatris enter into a significant global research and development collaboration
GlobeNewswire 16.02 Sosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head Offic...
GlobeNewswire 13.02 Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023
GlobeNewswire 22.01 Sosei Heptares Webinar Presentation for FY2023 Financial Results
GlobeNewswire 05.01 Sosei Group Announces Appointment of Experienced Pharmaceutical Executive Toshihiro Maeda as Chief O...
GlobeNewswire 07.12.2023 Sosei Group Announces Marketing Approval for PIVLAZ™ (clazosentan sodium) 150 mg in South Korea
GlobeNewswire 15.11.2023 Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer
GlobeNewswire 10.11.2023 Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine ...
GlobeNewswire 03.11.2023 New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at th...
GlobeNewswire 31.10.2023 Sosei Heptares Announces Submission of New Drug Application in Japan for Daridorexant (ACT-541468), ...
GlobeNewswire 25.10.2023 Sosei Heptares to Host R&D Day Highlighting its Innovative R&D and Late-Stage Development Progress
GlobeNewswire 16.10.2023 CRISPR Therapeutics Proposes New Appointment to the Board of Directors
GlobeNewswire 11.09.2023 Oculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Of...
GlobeNewswire 28.02.2022 Antares Pharma to Present at the Cowen 42nd Annual Healthcare Conference
GlobeNewswire 17.02.2022 Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating Results
GlobeNewswire 08.02.2022 Idorsia announces financial results for 2021 – 2022 to be a transformative year – Sustainable profit...